PubMed Health⌕ Search

PubMed · 9240242

Seizures in medically complex patients.

Abstract

Seizures are not an uncommon complication of medical conditions and should not be ascribed simply to "multifactorial" causes. Although many interacting factors may contribute to a lowered threshold for seizures, a careful systems-oriented search usually yields specific factors that are of primary importance. Not all medically complex patients with seizures have persistent or irreversible processes that lead to recurrent seizures or a need for maintenance antiepileptic drugs (AEDs). Because AEDs contribute to the potential for drug interactions, side effects, and toxicities in situations already encumbered with significant polypharmacy, the decision not to initiate such therapy can be even more important than selecting the best agent, best route of administration, and best dose from a growing list of AEDs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J G Boggs. 1997. Seizures in medically complex patients.. https://doi.org/10.1111/j.1528-1157.1997.tb04540.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗